版本:
中国

BRIEF-Nabriva Therapeutics announces enrollment completion for a phase 3 clinical trial evaluating lefamulin in community-acquired bacterial pneumonia

April 11 Nabriva Therapeutics Ag

* Nabriva Therapeutics announces enrollment completion for Leap 1, a phase 3 clinical trial evaluating lefamulin in community-acquired bacterial pneumonia

* Nabriva Therapeutics AG - Company anticipates availability of top-line clinical data from Leap 1 in Q3 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐